Skip to main content Skip to search Skip to main navigation
News: ICH

ICH: Parallel Guidances Q2(R2)/Q14 on Analytical Procedures adopted

The Assembly of the International Council for Harmonisation (ICH) adopted the revised Q2(R2) Guideline on the Validation of Analytical Procedures and the new Q14 Guideline on Analytical Procedure Development. They jointly describe the development and validation activities that should be applied during the life cycle of an analytical procedure to assess the quality of medicinal substances and products.

Both documents reached Step 4 of the ICH process, are now harmonised, and represent the current state of science and technology. This was announced following the ICH's 31 October 2023 meeting in Prague. Draft documents for the guidelines were first presented in March 2022 (we reported).

  • The scope of the revision of ICH Q2(R1) includes validation principles that cover the analytical use of spectroscopic or spectrometry data (e.g., NIR, Raman, NMR, or MS) some of which often require multivariate statistical analyses.
  • The new guideline Q14 provides principles relating to the description of the analytical procedure development process. It is intended to improve regulatory communication between industry and regulators and facilitate more efficient, sound scientific, and risk-based approval as well as post-approval change management of analytical procedures.

An Expert Working Group (EWG) will now transition to an Implementation Working Group (IWG) to develop training materials for both guidelines. Furthermore, the guidelines will be implemented and published shortly on the ICH website. This step is currently pending. The Q2(R2) and Q14 guidelines are intended to complement the ICH guidelines Q8 to Q12, as well as the current ICH guideline Q13 for continuous manufacturing.


Source:

ICH: Press Release on ICH Assembly Meeting, Prague, Oct 2023

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

Question of the Week | GMP-Verlag

What are the Benefits and Limitations of Passive Temperature-Controlled Containers for Drug Transport?

Here's the answer:
Read more
Outsourced Activities in the GDP Environment Part II: Contractual Agreements

Outsourced Activities in the GDP Environment Part II: Contractual Agreements

When outsourcing GDP activities, there is a need for concrete delimitation of responsibilities between a client and a contractor. Read more about the goals and the contents of a quality agreement in the following excerpt from GMP:KnowHow Pharmalogistics (GDP).

Read more
FDA: Adjustment of Nitrosamine Limits for Short-Term Use Medicines

FDA: Adjustment of Nitrosamine Limits for Short-Term Use Medicines

The FDA has updated its recommendations on Acceptable Intake (AI) limits for nitrosamine impurities. Under certain conditions, the Agency now accepts a Less-Than-Lifetime (LTL) adjustment of AI limits for medicinal products that are not intended for lifetime use. This also represents an alignment with the LTL concept of ICH M7(R2).
Read more
Swissmedic: SMS Registration Becomes Prerequisite for GMP Certificates

Swissmedic: SMS Registration Becomes Prerequisite for GMP Certificates

As of 15 November 2026, active substances must be registered in the EMA's Substance Management Services (SMS) database before Swissmedic can include them in establishment licences and GMP certificates for active substance manufacturers. The new requirement results from modifications to the EudraGMDP database.
Read more
News: EMA

EMA: New Q&As for Biological Medicinal Products

The EMA has added a new section to its Q&As on biological medicinal products addressing medicinal products containing secretomes or extracellular vesicles (EVs) obtained from human or animal cells.
Read more
News: Europe

EU: Council Adopts the Pharmaceutical Package

On 28 September 2026, the Council of the European Union adopted the EU pharmaceutical package, marking another important step in the legislative process for the comprehensive reform of EU pharmaceutical legislation.
Read more
Previous
Next